PE20161099A1 - Nuevos inhibidores de dgta2 - Google Patents
Nuevos inhibidores de dgta2Info
- Publication number
- PE20161099A1 PE20161099A1 PE2016000674A PE2016000674A PE20161099A1 PE 20161099 A1 PE20161099 A1 PE 20161099A1 PE 2016000674 A PE2016000674 A PE 2016000674A PE 2016000674 A PE2016000674 A PE 2016000674A PE 20161099 A1 PE20161099 A1 PE 20161099A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- dgta2
- new inhibitors
- treatment
- dgat2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula I o una sal farmaceuticamente aceptable donde R es H o -CH3. Tambien se refiere a un proceso de preparacion y a un metodo de tratamiento. Dicho compuesto tiene la capacidad de inhibir la enzima diacilglicerol O-aciltransferasa 2 (DGAT2), permitiendo, mediante la reduccion de los niveles de trigliceridos, controlar la produccion de LDL-c por medio de la secrecion de ApoB o la deposicion de esas particulas. Este compuesto es util en el tratamiento de hipercolesterolemia y enfermedades cardiovasculares como dislipidemias y ateroesclerosis
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908339P | 2013-11-25 | 2013-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20161099A1 true PE20161099A1 (es) | 2016-10-22 |
Family
ID=52016867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000674A PE20161099A1 (es) | 2013-11-25 | 2014-11-19 | Nuevos inhibidores de dgta2 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9073901B2 (es) |
| EP (1) | EP3074381B1 (es) |
| JP (1) | JP6155395B2 (es) |
| KR (1) | KR20160072252A (es) |
| CN (1) | CN105764889B (es) |
| AP (1) | AP2016009230A0 (es) |
| AR (1) | AR098394A1 (es) |
| AU (1) | AU2014353109B2 (es) |
| CA (1) | CA2928468A1 (es) |
| CL (1) | CL2016001172A1 (es) |
| CR (1) | CR20160216A (es) |
| DO (1) | DOP2016000120A (es) |
| EA (1) | EA201690847A1 (es) |
| ES (1) | ES2695302T3 (es) |
| HK (1) | HK1223367A1 (es) |
| IL (1) | IL245245A0 (es) |
| MA (1) | MA39048B1 (es) |
| MX (1) | MX2016006665A (es) |
| NZ (1) | NZ719444A (es) |
| PE (1) | PE20161099A1 (es) |
| PH (1) | PH12016500963A1 (es) |
| TN (1) | TN2016000146A1 (es) |
| TW (1) | TW201609668A (es) |
| WO (1) | WO2015077299A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2982267C (en) * | 2015-05-20 | 2019-11-12 | Eli Lilly And Company | Novel dgat2 inhibitors |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| EP4153584A1 (en) | 2020-05-18 | 2023-03-29 | Merck Sharp & Dohme LLC | Novel diacylglyceride o-acyltransferase 2 inhibitors |
| TW202229243A (zh) | 2020-10-08 | 2022-08-01 | 美商默沙東藥廠 | 作為新穎二醯基甘油酯o-醯基轉移酶2抑制劑之苯并咪唑酮衍生物的製備 |
| CA3198344A1 (en) | 2020-11-20 | 2022-05-27 | Patrick T. GUNNING | Methods and composition for kras modifications |
| WO2023026180A1 (en) | 2021-08-26 | 2023-03-02 | Pfizer Inc. | Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030170691A1 (en) | 2001-12-19 | 2003-09-11 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor |
| AU2003253925A1 (en) | 2002-07-18 | 2004-02-09 | Banyu Pharmaceutical Co., Ltd. | Combination therapy for the treatment of obesity |
| US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
| CN1997640A (zh) * | 2004-06-04 | 2007-07-11 | 艾尼纳制药公司 | 作为代谢调节剂的经取代芳基和杂芳基衍生物及其相关病症的预防和治疗 |
| EP1807102A2 (en) | 2004-10-29 | 2007-07-18 | Merck & Co., Inc. | Compositions and methods for the treatment of obesity and sexual dysfunction |
| WO2008129080A1 (en) | 2007-04-24 | 2008-10-30 | Ingenium Pharmaceuticals Gmbh | 4, 6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases |
| WO2011078102A1 (ja) * | 2009-12-22 | 2011-06-30 | 第一三共株式会社 | 新規フェノキシピリミジン誘導体 |
| WO2011087857A2 (en) | 2009-12-22 | 2011-07-21 | The Administrators Of The Tulane Educational Fund | Compositions and methods for treating obesity and diabetes |
| JP5921525B2 (ja) * | 2010-03-22 | 2016-05-24 | リード ディスカバリー センター ゲゼルシャフト ミット ベシュレンクテル ハフツング | 医薬的に活性のある二置換のトリアジン誘導体 |
| WO2012118563A2 (en) * | 2011-03-03 | 2012-09-07 | Vanderbilt University | 6-alkyl-n-(pyridin-2-yl)-4-aryloxypicolinamide analogs as mglur5 negative allosteric modulators and methods of making and using the same |
| EP2561867A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
| EP2562265A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Susceptibility to selective CDK9 inhibitors |
| EP2834238B1 (en) * | 2012-04-06 | 2017-02-01 | Pfizer Inc. | Diacylglycerol acyltransferase 2 inhibitors |
-
2014
- 2014-11-12 AR ARP140104254A patent/AR098394A1/es unknown
- 2014-11-13 TW TW103139445A patent/TW201609668A/zh unknown
- 2014-11-19 MX MX2016006665A patent/MX2016006665A/es unknown
- 2014-11-19 KR KR1020167013324A patent/KR20160072252A/ko not_active Application Discontinuation
- 2014-11-19 EP EP14809734.8A patent/EP3074381B1/en active Active
- 2014-11-19 TN TN2016000146A patent/TN2016000146A1/en unknown
- 2014-11-19 CA CA2928468A patent/CA2928468A1/en not_active Abandoned
- 2014-11-19 AP AP2016009230A patent/AP2016009230A0/en unknown
- 2014-11-19 NZ NZ719444A patent/NZ719444A/en not_active IP Right Cessation
- 2014-11-19 PE PE2016000674A patent/PE20161099A1/es not_active Application Discontinuation
- 2014-11-19 US US14/547,615 patent/US9073901B2/en active Active
- 2014-11-19 WO PCT/US2014/066339 patent/WO2015077299A1/en active Application Filing
- 2014-11-19 JP JP2016532611A patent/JP6155395B2/ja not_active Expired - Fee Related
- 2014-11-19 ES ES14809734T patent/ES2695302T3/es active Active
- 2014-11-19 EA EA201690847A patent/EA201690847A1/ru unknown
- 2014-11-19 CN CN201480064300.4A patent/CN105764889B/zh active Active
- 2014-11-19 AU AU2014353109A patent/AU2014353109B2/en not_active Ceased
- 2014-11-19 MA MA39048A patent/MA39048B1/fr unknown
-
2016
- 2016-04-20 IL IL245245A patent/IL245245A0/en unknown
- 2016-05-05 CR CR20160216A patent/CR20160216A/es unknown
- 2016-05-16 CL CL2016001172A patent/CL2016001172A1/es unknown
- 2016-05-24 DO DO2016000120A patent/DOP2016000120A/es unknown
- 2016-05-24 PH PH12016500963A patent/PH12016500963A1/en unknown
- 2016-10-06 HK HK16111635.0A patent/HK1223367A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016539115A (ja) | 2016-12-15 |
| AR098394A1 (es) | 2016-05-26 |
| WO2015077299A1 (en) | 2015-05-28 |
| CN105764889A (zh) | 2016-07-13 |
| IL245245A0 (en) | 2016-06-30 |
| DOP2016000120A (es) | 2016-06-15 |
| PH12016500963A1 (en) | 2016-06-20 |
| ES2695302T3 (es) | 2019-01-03 |
| CL2016001172A1 (es) | 2016-12-09 |
| AP2016009230A0 (en) | 2016-05-31 |
| MA39048A1 (fr) | 2017-05-31 |
| NZ719444A (en) | 2017-12-22 |
| CA2928468A1 (en) | 2015-05-28 |
| HK1223367A1 (zh) | 2017-07-28 |
| AU2014353109A1 (en) | 2016-05-12 |
| TW201609668A (zh) | 2016-03-16 |
| CR20160216A (es) | 2016-06-27 |
| EP3074381A1 (en) | 2016-10-05 |
| US9073901B2 (en) | 2015-07-07 |
| MX2016006665A (es) | 2016-07-26 |
| KR20160072252A (ko) | 2016-06-22 |
| MA39048B1 (fr) | 2018-04-30 |
| US20150148358A1 (en) | 2015-05-28 |
| JP6155395B2 (ja) | 2017-06-28 |
| TN2016000146A1 (en) | 2017-10-06 |
| EP3074381B1 (en) | 2018-07-04 |
| EA201690847A1 (ru) | 2016-09-30 |
| CN105764889B (zh) | 2018-01-02 |
| AU2014353109B2 (en) | 2017-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20161099A1 (es) | Nuevos inhibidores de dgta2 | |
| PH12018502534A1 (en) | Heteroaryl substituted pyridines and methods of use | |
| PH12017502201A1 (en) | Substituted pyridines and method of use | |
| PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| PH12017500829A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
| NZ730730A (en) | Novel carboxylic acid compounds useful for inhibiting microsomal prostaglandin e2 synthase-1 | |
| WO2012061428A3 (en) | Nicotinamides as jak kinase modulators | |
| WO2012143796A3 (en) | Anti-inflammation compounds | |
| NZ631337A (en) | Prodrugs of fumarates and their use in treating various diseases | |
| MY176814A (en) | Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis | |
| MX2015015412A (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| NZ707083A (en) | Anti-fibrotic pyridinones | |
| EA201391668A1 (ru) | Способы лечения или предупреждения связанных с холестерином расстройств | |
| MY183582A (en) | Deuterated cftr potentiators | |
| EA201391615A1 (ru) | Дейтерированные потенциаторы cftr | |
| MX2014003886A (es) | Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida. | |
| IN2014CN03803A (es) | ||
| WO2012173682A3 (en) | Compounds and methods for the treatment of isocitrate dehydrognase related diseases | |
| MX2021014663A (es) | Il-23a y tnf-alfa orientados y compuesto y sus usos. | |
| MY150437A (en) | Hydroxamate-based inhibitors of deacetylases b | |
| EP3147360A4 (en) | Coryneform bacterium transformant having high level expression of highly active variant enzyme and production method for 4-hydroxybenzoic acid using same or for salt thereof | |
| ZA201508750B (en) | Compounds of '3-(5-sustituted oxy-2,4-dinitro-phenyl)-2-oxo-propionic acid ester', process and applications thereof | |
| MY173914A (en) | Pesticidal composition and method for controlling pests | |
| WO2013172741A3 (ru) | Фторзамещенные (3r,4r,5s)-5-гуанидино-4-ациламино-3-(пентан-3-илокси) циклогексен-1-карбоновые кислоты, их эфиры и способ применения | |
| MX2021008768A (es) | Metodo para la produccion de acido 4-ciano benzoico o sus sales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |